愛博醫療(688050.SH)2021年度淨利潤預增65.7%-86.42%
格隆匯1月24日丨愛博醫療(688050.SH)公佈，公司預計2021年度實現歸屬於母公司所有者的淨利潤為1.6億元到1.8億元，與上年同期(法定披露數據)相比，將增加6344.17萬元到8344.17萬元，同比增加65.70%到86.42%。
公司預計2021年度實現歸屬於母公司所有者的扣除非經常性損益的淨利潤為1.4億元到1.56億元，與上年同期(法定披露數據)相比，將增加5032.08萬元到6632.08萬元，同比增加56.11%到73.95%。
報吿期淨利潤的增長主要源於公司核心產品人工晶狀體和角膜塑形鏡的銷量保持較快增長，營業收入增加。其中“普諾明”等系列人工晶狀體銷量與上年同期相比預計增長超過40%，“普諾瞳”角膜塑形鏡銷量與上年同期相比預計增長超過110%。
人工晶狀體：(1)境內，公司在各地區人工晶狀體集中帶量採購中廣泛中選，2021年度隨着集採政策逐步落地，終端客户數量持續增加，銷量穩定增長；(2)境外，隨着散光、EDoF相關人工晶狀體逐步獲得客户認可，在境外疫情依然嚴峻的情況下銷量取得大幅增長，與上年同期相比預計銷量增長超過50%。
角膜塑形鏡：行業整體仍處於上升期，公司依託獨特的產品設計、高效的產品供應、專業的培訓團隊不斷贏得客户信賴，同時加強了銷售團隊建設和市場推廣力度，品牌影響力逐步提升，銷量保持快速增長。
2021年第三、第四季度國內局部多發的新冠疫情，階段性導致了白內障和近視患者就診量減少，在一定程度上影響了公司業務增速。
2021年度公司為員工實施了股權激勵，計劃授予激勵對象45萬股限制性股票。報吿期內已向82名員工授予40.20萬股限制性股票。與上年同期相比，報吿期股份支付費用大幅增加。
2021年度公司研發項目增加且部分項目進入檢驗、樣品試製等費用投入較多環節，研發費用(費用化)增長較快，預計將超過收入增速。
2021年度非經常性損益較上年同期大幅增加，主要為公司利用閒置資金購買理財產品獲取的投資收益以及當期收到的上市補貼等政府補助增加所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
